Discover the full potential of Protein-Protein Interactions 

PROTEINA illuminates previously unseen Protein-Protein Interaction (PPI) networks to drive biomedical innovation.

Discover the power of our PPI platform to guide your research and development of next-generation precision medicines.

Tilt 1_2x.png
 
 

Our Technology

Which PPIs do we measure?

PROTEINA measures four molecular events to reconstitute PPI signatures.

The Science

Why do we
measure PPI?

Understand the biology of disease with our large-scale PPI data

Protein-Protein Interaction (PPI) profiling provides information about biological systems which is not accessible by genomic-based approaches.

 

With our proprietary PPI measurement technology, we can measure PPI information from pre-clinical to clinical samples.

 

Large-scale PPI data will advance research focused on discovering PPI biomarkers and therapeutic PPIs, and developing precision diagnostics. 

 

PPI reservoir

Proteins with a vacant binding pocket are potential candidates for PPI. Our proprietary technology can directly measure the strength of potential PPI.

dot-2.2.gif

Pre-formed PPI complex

Proteins form a large signaling complex as a functional module. This reflects the current situation of cell signaling in a sample.

dot 2.gif

Protein expression / PTM

Amounts and PTM status are the basis of PPI. We quantify them by preserving the delicate conformation of a target protein.

dots and square_1.gif

Molecular platform

A large protein complex is a signaling hub triggering many biological processes. We quantify the sizes and amounts of these molecular hubs with single-molecule imaging.

Tilt 2_2x.png

Visualizing and quantifying PPIs with single-molecule imaging

Single-molecule fluorescence imaging is the foundation of PROTEINA’s platform. We can visualize the signal from a single protein within a resolution of a few hundred nanometers.

PROTEINA’s high-throughput bio-signal harvester efficiently obtains a large amount of data for quantitative PPI signal analysis.

Proteina Machine.png

Our platform & Workflow

Fully automated multi-step workflow

Our fully automated, multi-step workflow, includes sample preparation, single-molecule imaging, and data analysis. Automation is a crucial factor for collecting and processing a large amount of data with high precision and consistency.

FA- 1.2 – 1.png

STEP 1

Sample Preparation with automated liquid handing processes 

FA- 2_2x.png

STEP 2

Automated Imaging process

FA- 3 – 1_2x.png

STEP 3

Data generation, Analysis, Model construction

Under the current workflow, PROTEINA has expanded the development of the measurable target proteins and can measure from biological samples approximately 100 types of distinct protein-protein interactions within two hours.

 

PROTEINA provides comprehensive solutions for diagnostics and drug development by analyzing the signal pathways in abnormal cells.

To play, press and hold the enter key. To stop, release the enter key.

Solutions background_2x.png

Generating comprehensive and robust PPI data from your samples

Solutions

PROTEINA’s single-molecule PPI analysis platform is a high-throughput PPI detection system designed to discover PPI networks for novel PPI biomarkers.

Applications include:

Basic research 2_2x.png

Basic Research

Our PPI data will broaden the understanding of cell signaling that leads to discovery of PPI biomarkers and novel therapeutic targets.

Clinical research 2_2x.png

Clinical Research

Consistent and rapid testing of protein expression and PPIs from clinical samples can accelerate clinical research. Our platform can serve as a novel diagnostic and monitoring device to reveal changes in PPI signatures during clinical trials.

Drug discovery 2_2x.png

Drug Discovery

Quantifying PPIs with our single-molecule imaging can be utilized as a high-throughput PPI drug discovery platform. With a customized PPI panel, you can quickly validate the biophysical properties of your novel drug candidates.

 
 

Pipeline

With the power of our solutions, PROTEINA is developing a novel, precision diagnostic strategy for tailored treatment of cancer and other diseases.

Pipeline-desktop_2x.png
 
Tilt 3_2x.png
About Protein background_2x_edited.jpg

About us

About Proteina

Our Story

PROTEINA was born in the lab at the Korea Advanced Institute of Science and Technology. We recognized early the importance of direct analysis of protein, since the product of a gene is inherently more complex and closer to function than the gene itself.This insight led to our founding as a biotechnology company.

 

PROTEINA developed the first-in-class Protein-Protein Interaction (PPI) analysis platform (“Single-Molecule Co-Immunoprecipitation Technology”) that enables quantitative PPI measurement at the single-molecule level.

 

PROTEINA has accumulated extensive know-how in developing assays measuring the targeted PPI as well as the analytic capability to model the efficacy of a drug based on its PPI metrics.

Our Mission

“With our novel technology, PROTEINA is analyzing proteins in a new way, developing effective, new approaches to diagnosing disease and discovering new drug candidates.”

Key Members

PROTEINA is led by an experienced and skilled team from diverse academic backgrounds, all sharing the goal of unlocking the full potential of direct PPI diagnostics in diseases.

Leaders

Tae Young Yoon, Ph.D. (CEO)

As founder and Chief Executive Officer, Tae-Young Yoon, PhD is responsible for directing all aspects of company strategy, planning, and operations. Although Dr. Yoon started his research career as an electrical engineer, studying liquid crystal display technologies, he made a bold switch to the field of biophysics in the middle of his graduate study. After starting his own research lab at KAIST, Dr. Yoon was named as a principal investigator of the National Creative Research Initiative of South Korea and one of the first awardees of Samsung Research Foundation Grant. These unconditional supports enabled Dr. Yoon’s research team to explore a technique studying protein-protein interactions vastly different from conventional ones.

Dr. Yoon founded PROTEINA in 2015 with a vision of generating large-scale, quantitative data at the level of protein-protein interactions. Dr. Yoon is currently a professor in the school of biological sciences and a member of the future research committee of Seoul National University.

Hongwon Lee, Ph.D. (CTO)

Hongwon was named PROTEINA’s Chief Technology Officer in December of 2018 and served as a member of PROTEINA’s board of directors since May 2020. He previously served as the company’s senior principal scientist since 2017.

 

He leads early-stage research, PPI biomarker discovery, and clinical device development for successful product development and commercialization of PROTEINA’s research portfolio. He is passionate about translating PROTEINA’s technology into a precision diagnostic platform to help cancer patients more.

Daiseung Lee, U.S. CPA (CFO)

Daiseung Lee has served as a Chief Financial Officer since 2020. He leads Proteina’s finance, regulatory affairs, intellectual property, human resources, investor relations, and administrative teams.

 

Before joining Proteina, as a US CPA, Mr. Lee worked for Kim & Chang Law Office with extensive experiences representing foreign and domestic clients in corporate finance advisory practices ranging from customs & international trade, international arbitration, tax, due diligence, and corporate investigation.

Researchers

Byoungsan Choi, Ph.D. (Principal Researcher)

Byoungsan began his career at Proteina in 2018 as a Principal Researcher and currently leads a team focusing on development of BTKi biomarker. His team is also working on two PPI drug projects along with applying PPI into FFPE samples. He developed Proteina’s imaging device with Osong KBIO Health.

 

Byoungsan holds a Ph.D. as well as a B.S. in Physics from Korea Advanced Institute of Science and Technology (KAIST), South Korea.

Hyunwoo Kim, Ph.D. (Chief Researcher)

Hyunwoo Kim, Ph.D. is a Chief Researcher at Proteina. Dr. Kim is conducting research on PPI of HER family proteins and discovery of biomarkers related to -IAP (Inhibitory of apoptosis pathway) proteins. He is also involved in a project to develop an automated single molecule PPI signal measurement machine. 

He received his Ph.D. in biophysics at Korea Advanced Institute of Science and Technology (KAIST).

Shi Ho Kim, Ph.D. (Chief Researcher)

Shi Ho Kim, Ph.D., joined Proteina as a Chief Researcher in July 2021 and is currently leading a project on developing a high throughput cancer diagnosis kit based on his expertise in super-resolution optical microscopy along with DNA photo-lithography. 

Dr. Kim received his B.S. in Chemistry Magna Cum Laude from Stony Brook University and a Ph.D. in Physical Chemistry at the Pennsylvania State University.

Regulatory and IP

So-Young Yoon
(Regulatory Affairs Team Leader)

So-young Yoon oversees Proteina’s regulatory strategy throughout the countries Proteina is aiming for including Korea and US, etc.

 

Prior to joining Proteina, as a qualified Registerned Nurse in Australia, she worked in Cancer center and Oncology-Hematology unit for 9 years.

Jiyoung Ryu, Ph.D. (Principal Researcher)

Ji Young Ryu, Ph.D. joined Proteina in 2018. Dr. Ryu led product design and manufacturing projects successfully by getting an approval for GMP in South Korea. Currently, she is leading Proteina’s product development team.

 

Ji Young received her B.A./M.A./Ph.D. in Physics from Korea Advanced Institute of Science and Technology (KAIST).

Kyung Chan Park, Ph.D. (Chief Researcher)

Kyung Chan Park is a Chief Researcher at Proteina, leading a biomarker discovery team for the development of inflammasome biomarker. He has expertise in cancer cell biology and anti-cancer therapeutic development with 16 peer-reviewed publications.

 

Kyung Chan received B. Sc., Grad. Dip. Sc. and Ph.D. in Medicine and Health from the University of Sydney, Australia.

So Yi Jeong
(Patent Attorney, Intellectual Property Team Leader)

So Yi Jeong is Proteina’s in-house patent attorney. She manages our intellectual property rights and strives to build a strong IP portfolio with global competitiveness.

 

Before joining Proteina, she worked for the IPS patent law office with extensive experience in application for patents/trademarks/ designs, IP consulting, supporting technology commercialization/ technology transaction, and patent trial/litigation.

 

She received her bachelor’s degree in biology from Jeonbuk University, Korea, in 2010.

Publications

Nature communcations_2x.png

Real-time single-molecule co-immunoprecipitation analyses reveal cancer-specific Ras signalling dynamics

Nature protocols_2x.png

Real-time single-molecule coimmunoprecipitation of weak protein-protein interactions

Nature biomedical engineering_2x.png

Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors

elife_2x.png

Profiling protein–protein interactions of single cancer cells with in situ lysis and coimmunoprecipitation

Lab on a chip_2x.png

Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers

logologologo2_대지 1.png

DISCOVER the full potential

of Protein-Protein Interactions

For more information

Contact us

070-4276-5261 (+82-70-4276-5261)

Rm 211, The Institute of Molecular Biology & Genetics (Bldg. 105), Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, Korea (Postal Code 08826)